Boston Scientific Corp. (NYSE:BSX)

The revenue data reflects diverse trends across various business segments over the five-year period.

Endoscopy

The segment shows a generally positive trend with revenue increasing from $1,762 million in 2018 to $2,221 million in 2022. There was a slight dip in 2020, likely influenced by external factors, followed by recovery and growth in subsequent years.

Urology

Revenue experienced moderate fluctuation, increasing from $1,245 million in 2018 to $1,413 million in 2019, declining in 2020 to $1,286 million, but then climbing steadily to reach $1,773 million in 2022, indicating strong growth post-2020.

Neuromodulation

Revenues rose from $779 million in 2018 to $873 million in 2019, dipped to $761 million in 2020, and then showed gradual growth to $917 million in 2022. The segment displays some volatility but an overall upward trajectory in the long term.

MedSurg

MedSurg experienced consistent growth with revenues advancing from $3,786 million in 2018 to $4,911 million in 2022, despite a slight decline in 2020. The segment presents a strong rebound and steady expansion thereafter.

Interventional Cardiology Therapies

This segment shows a decrease from $2,590 million in 2018 to $1,975 million in 2020, followed by moderate recovery to $2,228 million in 2022. The initial decline and partial rebound suggest challenges faced during the mid-period.

Watchman

Watchman revenue data is available from 2020 onward, showing rapid growth from $324 million in 2020 to $1,019 million in 2022. This notable increase highlights a strong emerging contribution to overall revenue.

Cardiac Rhythm Management

The segment remains relatively stable with minor fluctuations, moving from $1,951 million in 2018 to $2,100 million in 2022, although it experienced a decline in 2020 before recovering over the following years.

Electrophysiology

There is a consistent upward trend with revenue steadily increasing from $311 million in 2018 to $585 million in 2022, indicating solid growth momentum in this segment.

Cardiology

Cardiology shows a decline from $4,852 million in 2018 to $4,290 million in 2020, with a significant recovery thereafter, reaching $5,932 million in 2022. This suggests the segment overcame short-term setbacks and expanded robustly.

Peripheral Interventions

This segment exhibits continuous growth throughout the period, with revenues rising from $1,187 million in 2018 to $1,899 million in 2022, reflecting consistent demand and expansion.

Cardiovascular

Cardiovascular revenues declined from $6,039 million in 2018 to $5,867 million in 2020 but recovered strongly to $7,831 million in 2022, demonstrating resilience and solid growth after a challenging period.

Other

The category shows irregular performance, with revenue of $81 million in 2019, peaking at $219 million in 2020, dropping sharply to $13 million in 2021, and a negative value of -$60 million in 2022. This volatility may imply one-off items or restructuring effects impacting this category.

Net Sales

Overall net sales display a generally positive upward trend, increasing from $9,825 million in 2018 to $12,682 million in 2022. Despite a temporary downturn in 2020, the revenue base has expanded significantly over the five-year span.